Qube Research & Technologies LTD Prothena Corp Public LTD CO Call Options Transaction History
Qube Research & Technologies LTD
- $93.8 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PRTA
# of Institutions
214Shares Held
33.7MCall Options Held
879KPut Options Held
791K-
Black Rock Inc. New York, NY3.86MShares$40.7 Million0.0% of portfolio
-
Adar1 Capital Management, LLC Austin, TX3.38MShares$35.6 Million3.14% of portfolio
-
Armistice Capital, LLC New York, NY2.24MShares$23.6 Million0.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.05MShares$21.6 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA1.27MShares$13.5 Million1.75% of portfolio
About PROTHENA CORP PUBLIC LTD CO
- Ticker PRTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,922,800
- Market Cap $496M
- Description
- Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...